Menopausal hormone therapy in systemic lupus erythematosus: Pro et contra
https://doi.org/10.47360/1995-4484-2023-70-76
Abstract
The emergence of modern methods of treatment of systemic lupus erythematosus (SLE) has led to an increase in the duration and quality of life of patients with this disease. However, the majority of patients with SLE are women, and it is well known that the female sex hormone estrogen can influence the activity of systemic autoimmune diseases, including SLE. An increase in life expectancy means an increase in the length of a postmenopausal woman’s stay, with the possibility of the appearance of classic menopausal disorders, and the development or aggravation of comorbid pathologies, primarily osteoporosis and cardiovascular diseases, as well as the need to improve the quality of life for women with these diseases. This review collects and analyzes data on the risks and benefits of using menopausal hormone therapy for SLE.
About the Authors
T. S. Panevin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
T. V. Popkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
N. M. Kosheleva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Russian Federation, Moscow, Kashirskoye Highway, 34A
A. V. Ledina
People’s Friendship University of Russia
Russian Federation
Russian Federation
117198, Russian Federation, Moscow, Miklukho-Maklaya str., 6
References
1. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277-A287. doi: 10.1016/j.autrev.2009.12.008
2. Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001;30(6):426-435. doi: 10.1053/sarh.2001.22498
3. Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A. Association of polymorphisms of the oestrogen receptor alpha gene with the age of menarche. Hum Reprod. 2002;17(4):1101-1105. doi: 10.1093/humrep/17.4.1101
4. Johansson M, Arlestig L, Möller B, Smedby T, Rantapää-Dahlqvist S. Oestrogen receptor {alpha} gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(11):1611-1617. doi: 10.1136/ard.2004.032425
5. Boddaert J, Huong DLT, Amoura Z, Wechsler B, Godeau P, Piette JC. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83(6):348-359. doi: 10.1097/01.md.0000147737.57861.7c
6. Tomic-Lucic A, Petrovic R, Radak-Perovic M, Milovanovic D, Milovanovic J, Zivanovic S, et al. Late-onset systemic lupus erythematosus: Clinical features, course, and prognosis. Clin Rheumatol. 2013;32(7):1053-1058. doi: 10.1007/s10067-013-2238-y
7. Lalani S, Pope J, de Leon F, Peschken C; Members of CaNIOS/1000 Faces of Lupus. Clinical features and prognosis of lateonset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol. 2010;37(1):38-44. doi: 10.3899/jrheum.080957
8. Kosheleva NM, Alekberova ZS, Nasonova VA, Karabaeva AS. Systemic lupus erythematosus: Onset in people over 45 years of age. Clinical Gerontology. 2002;3:16-21 (In Russ.).
9. Fernández M, Calvo-Alén J, Alarcón GS, Roseman JM, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum. 2005;52(6):1655-1664. doi: 10.1002/art.21048
10. Urowitz MB, Ibañez D, Jerome D, Gladman DD. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol. 2006;33(11):2192-2198.
11. Sukhikh GT, Smetnik VP, Andreeva EN, Balan VE, Gavisova AA, Grigoryan OR, et al. Menopausal hormone therapy and maintaining the health of women in adulthood. Russian Journal of Human Reproduction. 2018;24(S6):727-756 (In Russ.).
12. Sammaritano L, Patterson K, Lockshin M, et al. Current use of estrogen replacement therapy in postmenopausal systemic lupus erythematosus patients: increase since inception of the SELENA trial. Arthritis Rheum. 1999;42(Suppl 9):197.
13. Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? J Clin Rheumatol. 1995;1(4):205-212. doi: 10.1097/00124743-199508000-00002
14. Buyon JP, Wallace DL. The endocrine system, use of exogenous estrogens, and the urogenital tract. In: Wallace DJ, Hahn BJ (eds). Dubois’ lupus erythematosus; 5th ed. Baltimore:William et Wilkins; 1997:817-834.
15. Adamyan LV, Andreeva EN, Apolikhina IA Artymuk NV, Ashrafyan LA, Balan VE, et al. Menopause and menopause in women: Clinical guidelines. Moscow; 2021 (In Russ.).
16. Holroyd CR, Edwards CJ. The effects of hormone replacement therapy on autoimmune disease: Rheumatoid arthritis and systemic lupus erythematosus. Climacteric. 2009;12(5):378-386. doi: 10.1080/13697130903025449
17. Gompel A. Systemic lupus erythematosus and menopause. Climacteric. 2020;23(2):109-115. doi: 10.1080/13697137.2019.1679113
18. Gompel A, Piette JC. Systemic lupus erythematosus and hormone replacement therapy. Menopause Int. 2007;13(2):65-70. doi: 10.1258/175404507780796433
19. Sánchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122(6): 430-433. doi: 10.7326/0003-4819-122-6-199503150-00005
20. Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol. 1998;25(8): 1515-1519.
21. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56(4):1251-1262. doi: 10.1002/art.22510
22. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med. 2005; 142(12 Pt 1):953-962. doi: 10.7326/0003-4819-142-12_part_1-200506210-00004
23. Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, Lara-Reyes P, Jiménez-Santana L, Romero-Díaz J, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum. 2007;56(9):3070-3079. doi: 10.1002/art.22855
24. Arden NK, Lloyd ME, Spector TD, Hughes GR. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus. 1994;3(1):11-13. doi: 10.1177/096120339400300104
25. Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone replacement therapy in systemic lupus erythematosus. J Rheumatol. 1997;24(11):2149-2152.
26. Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol. 1998; 27(5):342-346. doi: 10.1080/03009749850154357
27. Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg ÁM. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: A systematic review and metaanalysis. PLoS One. 2014;9(8):e104303. doi: 10.1371/journal.pone.0104303
28. Sanches-Guerrero J, Romero-Diaz J, Mendoza-Fuentes A, Mendoza-Peralta M, del Carmen Cravioto M. Menopause in systemic lupus erythematosus. Age at menopause and clinical characteristics. Arthritis Rheum. 1999;42(Suppl 9):205.
29. Alpízar-Rodríguez D, Romero-Díaz J, Sánchez-Guerrero J, Seuc AH, Cravioto Mdel C. Age at natural menopause among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2023-2029. doi: 10.1093/rheumatology/keu222
30. González LA, Pons-Estel GJ, Zhang JS, McGwin G Jr, Roseman J, Reveille JD, et al.; LUMINA Study Group. Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). Lupus. 2009;18(2):184-186. doi: 10.1177/0961203308098988
31. Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al.; PLUS group. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98(9):3785-3792. doi: 10.1210/jc.2013-1235
32. Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: Evaluation by using anti-Muellerian hormone. Lupus. 2011;20(11):1193-1197. doi: 10.1177/0961203311409272
33. Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-627. doi: 10.3109/09513590.2011.650752
34. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831-837. doi: 10.1002/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1
35. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus – Proposed guidelines for risk factor management. Rheumatology (Oxford). 2004;43(1):7-12. doi: 10.1093/rheumatology/keg436
36. Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum. 2003;48(11):3159-3167. doi: 10.1002/art.11296
37. Popkova TV, Alekberova ZS, Aleksandrova EN, Bulgakova OK, Nassonov EL. Cardiovascular disturbances and atherosclerosis risk factors in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2004;42(4):10-14 (In Russ.).
38. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683-686. doi: 10.1191/0961203305lu2200oa
39. Ribeiro GG, Bonfá E, Sasdeli Neto R, Abe J, Caparbo VF, Borba EF, et al. Premature coronary artery calcification is associated with disease duration and bone mineral density in young female systemic lupus erythematosus patients. Lupus. 2010;19(1):27-33. doi: 10.1177/0961203309345778
40. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi: 10.1001/jama.288.3.321
41. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613. doi: 10.1001/jama.280.7.605
42. Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG. Meno pause-associated risk of cardiovascular disease. Endocr Connect. 2022;11(4):e210537. doi: 10.1530/EC-21-0537
43. Hochman J, Urowitz MB, Ibañez D, Gladman DD. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. Lupus. 2009;18(4):313-317. doi: 10.1177/0961203308097475
44. Singh NK, Agrawal A, Singh MN, Kumar V, Godhra M, Gupta A, et al. Prevalence and pattern of antiphospholipid antibody syndrome in a hospital based longitudinal study of 193 patients of systemic lupus erythematosus. J Assoc Physicians India. 2013;61(9):623-626.
45. Gris JC, Bourguignon C, Bouvier S, Nouvellon É, Laurent J, Perez-Martin A, et al. Combined oral contraceptive-associated venous thromboembolism revealing an antiphospholipid syndrome: International retrospective study of outcomes. Thromb Res. 2022;219:102-108. doi: 10.1016/j.thromres.2022.09.013
46. Kryukov EV, Panevin TS. Antithrombogenic vessel wall activity in women with climacteric myocardiodys trophy during the period of peri- and postmenopause. Bulletin of Pirogov National Medical & Surgical Center. 2020;15(2):67-70 (In Russ.). doi: 10.25881/BPNMSC.2020.26.26.010
47. Kryukov EV, Panevin TS, Popova LV. Age-related changes in the hemostasis system. Clinical Medicine (Russian Journal). 2020;98(1):9-12 (In Russ.) doi: 10.34651/0023-2149-2020-98-1-9-12
48. Kryukov EV, Popova LV, Vasiliev SV, Panevin TS, Panevina AS, Stromskaya UA, et al. Ultra-low dose estradiol plus dydrogesterone: A role in prevention of the development and progression of atherosclerosis. Bulletin of the Russian Military Medical Academy. 2021;23(1):9-14 (In Russ.). doi: 10.17816/brmma63562
49. Ramsey-Goldman R, Mattai SA, Schilling E, Chiu YL, Alo CJ, Howe HL, et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med. 1998;46(5):217-222.
50. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550-2557. doi: 10.1002/art.21955
51. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529-556. doi: 10.1002/art.41191
52. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770
Review
For citations:
Panevin T.S., Popkova T.V., Reshetnyak T.M., Kosheleva N.M., Ledina A.V. Menopausal hormone therapy in systemic lupus erythematosus: Pro et contra. Rheumatology Science and Practice. 2023;61(1):70-76. (In Russ.) https://doi.org/10.47360/1995-4484-2023-70-76
Views:
1337
Email this article 